Acrivon doses first patient in Phase 1 trial of WEE1/PKMYT1 inhibitor ACR-2316

Acrivon Therapeutics, Inc.

First patient dosed two quarters ahead of original timeline for ACR-2316 Phase 1 trial in solid tumors.
ACR-2316 advanced from initial lead to Phase 1 in 15 months using AP3 platform.
Initial clinical data from monotherapy dose optimization expected in 2H 2025.
Trial assesses safety, tolerability, MTD, RP2D, PK, and anti-tumor activity per FDA Project Optimus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.